RENBP and neoplasm: Circulating cDC1s isolated from leukapheresis products of patients, eventually undergoing additional treatments with FLT3L to enhance cDC1 numbers, can then be shortly exposed to autologous tumor-Ag and adjuvant before reinfusion.